Exclusivity Patents and exclusivity Drug Information Prescribing and other information DMFs Type 2 master files Databases Free access to database search 21 CFR FDA regulations for this API Federal Register FR search results for this API Drug Recalls For Rx's using this API

FDA Approval Activities for this Drug… Avalide (irbesartan/hydrochlorothiazide) Tablets,72/12.5, 150/12.5, & 300/12.5 mg, Bristol-Myers Squibb NDA 20-758/S16 Avapro (irbesartan) Tablets, 75, 150, & 300 mg, Sanofi-Synthelabo, NDA 20-757/S22 7/19/02 7/24/02 Avapro (irbesartan) Tablets, 75, 150, & 300 mg, Sanofi-Synthelabo, NDA 20-757/S21 9/17/02 9/20/02 9/17/02 11/22/02 Avapro (irbesartan) Tablets, 75, 150, & 300 mg, Bristol-Myers Squibb NDA 20-757/S16 5/10/00 6/6/01 Avapro (irbesartan) Tablets, 75, 150, & 300 mg, Bristol-Myers Squibb NDA 20-757/S15 5/9/00 6/6/01 Avapro (irbesartan) Tablets, Bristol-Myers Squibb NDA 20-757/S14 5/26/01 12/4/01 Avapro HCT Tablets, 75/12.5 & 150/12.5 Bristol-Myers Squibb NDA 20-758/S-003 8/31/98 3/10/00 | Avalide (irbesartan/hydrochlorothiazide) Tablets, Sanofi-Synthelabo, Formulation Revision | Avapro (irbesartan) Tablets, Sanofi-Aventis, Labeling Revision | Avalide (irbesartan/hydrochlorothiazide) Tablets, Sanofi-Aventis, Labeling Revision | Avapro (irbesartan) Tablets, Bristol-Myers Squibb, Labeling Revision | Avapro (irbesartan) Tablets, Sanofi-Aventis, Labeling Revision | Avalide (irbesartan-hydrochlorothiazide) Tablets, Sanofi-Aventis, Labeling Revision | Avapro (irbesartan) Tablets, Sanofi-Aventis, Labeling Revision Check the most up-to-date list of FDA Approvals.                                                                                      A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U-Z Health Topics | News Feed for each API | DMF Index | Pharma Job Search | FindingHealthOnline © 2009 Betterchem.com